• Corpus ID: 33313274

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.

@article{Dhodapkar1997PhaseIT,
  title={Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.},
  author={Madhav V. Dhodapkar and Joseph Rubin and Joel M Reid and Patrick A. Burch and Henry C. Pitot and Jan C. Buckner and Matthew M. Ames and Vera J. Suman},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1997},
  volume={3 7},
  pages={
          1093-100
        }
}
  • M. Dhodapkar, J. Rubin, +5 authors V. Suman
  • Published 1 July 1997
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
Temozolomide (TMZ) is a new imidazotetrazine derivative with early clinical activity in glioma and melanoma. The purpose of this Phase I study is to characterize the toxicity, pharmacokinetics, and antitumor activity of TMZ administered on an oral 5-day schedule to patients with or without prior exposure to nitrosourea (NU). Thirty-six eligible patients received a total of 77 cycles of therapy with TMZ administered p.o. at doses ranging from 50 mg/m2/day to 250 mg/m2/day for 5 days, every 4… 
A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer.
TLDR
This dose and schedule of Temozolomide had insignificant activity in this heavily pretreated group of patients with persistent or recurrent ovarian or primary peritoneal carcinoma.
Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease
TLDR
The combination of docetaxel and temozolomide was well tolerated and these agents can be safely combined.
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
TLDR
The toxicities, recommended dose, and pharmacological profile of the TMZ/CDDP combination are determined and the recommended doses for Phase II clinical trials are TMZ 200 mg/m2/day for 5 days with 75 mg/ m2 CDDP on day 1, every 4 weeks.
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
PURPOSE To determine the principal toxicities, characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of temozolomide (TMZ) on a daily-for-5-days schedule, and recommend a dose for
Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
TLDR
Vorinostat in combination with temozolomide is well tolerated in patients with high-grade glioma and a phase I/II trial of vor inostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway.
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
  • K. Vera, L. Djafari, +8 authors E. Raymond
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2004
TLDR
Temozolomide can be given safely using a dose-dense regimen of 300 mg/m(2)/day for 3 consecutive days every 2 weeks in patients with recurrent brain tumors.
Temozolomide and cisplatin in avdanced malignant melanoma.
TLDR
The combination of TMZ and CDDP seems to be active in untreated patients with advanced melanoma, and absence of recurrence in the majority (5/9; 56%) of CR patients seems to indicate that IFN may act on the duration of the response to chemotherapy.
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
TLDR
When given orally once daily for 5 days, temozolomide was well tolerated and produced a non-cumulative, transient myelosuppression, the most common non-haematological toxicities were mild to moderate nausea and vomiting.
Temozolomide
Abstract▴ Temozolomide is an imidazotetrazine derivative of the alkylating agent dacarbazine. It undergoes chemical conversion to the active species 5-(3-mefhyl-1-triazeno)imidazole-4-carboxamide
Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma
TLDR
It is suggested that TMZ may achieve similar efficacy to TMZ/DOX whilst being associated with a lower frequency of recorded toxicities, which may have gone undetected due to the absence of associated clinical signs.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
TLDR
Temozolomide in the schedule used has as good activity in chemotherapy-naive metastatic melanoma as the other most active agents currently in use.
Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.
TLDR
Temozolomide was well tolerated with little subjective toxicity and usually predictable myelosuppression and is a promising new drug in the treatment of primary brain tumours.
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
TLDR
In the extended Phase I trial temozolomide only occasionally exhibited the unpredictable myelosuppression seen with mitozolmide, which is easy to use clinically and generally well tolerated.
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
TLDR
It is suggested that temozolomide may be active in the treatment of a broad spectrum of central nervous system cancers, including Mer+ tumors resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
TLDR
The schedule-dependent anti-tumour activity of temozolomide seen in experimental models and clinics may be related to a cumulative depletion of ATase, which is measured in extracts of peripheral blood mononuclear cells taken from eight patients at various times during 5 days of oral treatment with temozlomide.
Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
TLDR
Data suggest that temozolomide might have activity against non-seminomatous testicular germ cell tumours which have relapsed following cisplatin-containing chemotherapy, and could have a role in the treatment of patients with metastatic lesions in the brain.
NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.
TLDR
Molecular modeling of the structure of Temozolomide indicates that the prodrug can make a favorable noncovalent encounter with DNA and the known structure-activity relationships as well as the biological and clinical properties of temozolmide can be interpreted in terms of this model.
Exceptional sensitivity of testicular germ cell tumor lines to the new anti-cancer agent
  • tetnozolomide. Br. J. Cancer
  • 1995
Preclinical activity of temozolomide in mice : efficacy against human brain tumor xenografts and synergism with I . 3bis ( 2chloroethyl )1nitrosourea
  • Br . J . Cancer .
  • 1995
Depletion of O#{244} aIkylguanine DNA alkyltransferase correlates with potentiation of teniozolomide and CCNU toxicity in human tumor cells
  • Br. J. Cancer
  • 1993
...
1
2
...